## Protocol Section
### Identification Module
**NCT ID:** NCT05606679

**Brief Title:** Maternal KIR and Fetal HLA Influence Reproductive Success in ART-oocyte Donor.

**Official Title:** Maternal KIR and Fetal HLA Influence Reproductive Success in ART-oocyte Donor.

#### Organization Study ID Info
**ID:** 2207-MAD-098-DA
#### Organization
**Class:** OTHER
**Full Name:** IVI Madrid
### Status Module
#### Completion Date
**Date:** 2025-12-31

**Type:** ESTIMATED

#### Expanded Access Info
#### Last Update Post Date
**Date:** 2024-01-11

**Type:** ACTUAL

**Last Update Submit Date:** 2024-01-10

**Overall Status:** RECRUITING

#### Primary Completion Date
**Date:** 2024-12-01

**Type:** ESTIMATED

#### Start Date
**Date:** 2022-11-01

**Type:** ACTUAL

**Status Verified Date:** 2024-01

#### Study First Post Date
**Date:** 2022-11-07
**Type:** ACTUAL
**Study First Submit Date:** 2022-10-31
**Study First Submit QC Date:** 2022-10-31
### Sponsor Collaborators Module

#### Collaborators

**Class:** UNKNOWN

**Name:** Diana Alecsandru

#### Lead Sponsor

**Class:** OTHER

**Name:** IVI Madrid

#### Responsible Party

**Type:** SPONSOR

### Oversight Module

**Is FDA Regulated Device:** False

**Is FDA Regulated Drug:** False

**Oversight Has DMC:** False

### Description Module

**Brief Summary:** The present project is an ambispective study designed to answer how HLA-F SNPs, as well as KIR-HLA-C compatibility, influence reproductive outcomes in oocyte donation cycles. On the one hand, healthy patients without history of RIF and RM and with indication of egg donation cycle as ART treatment will be genotype for KIR, HLA-C and HLA-F. HLA-C from male partners and egg donors will be also analyzed. No matching based on HLA-C genotypes would be performed and donors would be assigned to recipients following the routine clinical practices. After SET, patients will be followed up until delivery or until the end of treatment. On the other hand, access to data from patients who have equally undergone oocyte-donation cycles, who meet the inclusion criteria and who have been genotyped for KIR and HLA-C as a matter of routine practice, will be requested.

For this study, only the first SET of oocyte-donation that patients undergo will be considered. LBR will be the primary endpoint of the study. In addition, secondary endpoints such as embryo development, sustained implantation, progesterone levels, implantation failure, miscarriage rate and unwanted events (preeclampsia, fetal grow restriction, premature birth, low birth weight...) will also be evaluated.

**Detailed Description:** This is an ambispective study in which healthy patients without history of RIF and RM and with indication of egg donation cycle as ART treatment will be genotyped for KIR, HLA-C and HLA-F. Male partners and egg donors will also be studied for their HLA-C alleles. Patients would be assigned to donors, following routine clinical practice, without matching based on donor's HLA-C genotype. They would undergo SET and be followed up until delivery.

In addition to this prospective part, we will request access to data from patients who have equally undergone oocyte donation cycles at the clinic, who meet the inclusion criteria and who have been genotyped for KIR and HLA-C as a matter of routine practice.

Combinations of maternal KIR and HLA-C genotypes of the egg donor and fetus (based on the genotypes of the donor and male partner), as well as different HLA-F SNP genotypes of the recipients (form the prospective part of this proyect) will be correlated with reproductive outcomes. LBR will be the primary endpoint of the study. In addition, secondary endpoints such as embryo development, sustained implantation, progesterone leves, implantation failure and miscarriage rate will also be evaluated. Obstetrical complications such as preeclampsia, premature birth (\<34 weeks) and low birth weight will also be evaluated.

### Conditions Module

**Conditions:**

- Reproductive Issues

### Design Module

#### Design Info

**Observational Model:** OTHER

**Time Perspective:** OTHER

#### Enrollment Info

**Count:** 400

**Type:** ESTIMATED

**Study Type:** OBSERVATIONAL

### Arms Interventions Module

#### Arm Group 1

**Description:** Healthy patients with no history of RIF and RM which have undergone or are undergoing ART with oocyte donation and SET.

**Intervention Names:**

- Genetic: Analysis combinations of maternal KIR and HLA-C genotypes

**Label:** Patients undergoing ART with oocyte donation

### Interventions

#### Intervention 1

**Arm Group Labels:**

- Patients undergoing ART with oocyte donation

**Description:** Analysis of combinations of maternal KIR and HLA-C genotypes of the egg donor and fetus (based on the genotypes of the donor and male partner), as well as different HLA-F SNP genotypes of the recipients

**Name:** Analysis combinations of maternal KIR and HLA-C genotypes

**Type:** GENETIC

### Outcomes Module

#### Primary Outcomes

**Description:** Principally, to establish whether patients of KIR AA and KIR Bx (2DS1-) genotypes show better outcomes when receiving oocytes from HLA-C1C1 donors than from donors with at least one HLA-C2 allele.

**Measure:** To determine if certain combinations of maternal KIR and oocyte donor HLA-C genotypes results in improved outcomes of live birth rate.

**Time Frame:** 36 months

#### Secondary Outcomes

**Description:** To determine if certain combinations of maternal KIR and oocyte donor HLA-C genotypes results in improved outcomes of live birth rathe, in the same way as in the primary target, but taking into account the extra HLA-C2 alleles of the embryo with respect to the mother and the alternative division of the maternal genotypes into KIR AA, AB and BB.

**Measure:** To determine if certain combinations of maternal KIR and oocyte donor HLA-C genotypes results in improved outcomes of live birth rate taking into account the extra HLA-C2 alleles of the embryo.

**Time Frame:** 36 months

### Eligibility Module

**Eligibility Criteria:** Inclusion Criteria:

* Patients who have undergone or are undergoing their first egg donation cycle.
* Between 18 and 45 years of age.
* BMI between 19 and 25 kg/m2
* Signed written informed consent submitted.
* No history of RIF, defined as implantation failure after 4 consecutive blastocysts are transferred.
* No history of RM, defined as the presence of 2 or more clinical miscarriages.
* Normal blood pressure and viral serology.

Exclusion Criteria:

* Male partner diagnosed with severe male factor
* Patients who test positive for thrombophilic disorders (factor V Leiden, prothrombinG20210A mutation, positive antiphospholipid antibodies)
* Participation in a different study or clinical trial with a research drug or device in the last three months prior to recruitment.
* Known abnormal karyotype of subject or of her partner
* Any known clinically significant systemic disease
* Known inherited or acquired thrombophilia disease.
* Any known endocrine or metabolic abnormalities with the exception of controlled thyroid function disease.
* Severe psychiatric conditions.
* Patients with uterine factor/abnormalities (eg. myomas, polyps, adenomyosis, etc), that determines an unsatisfactory ultrasound for their ART.
* Patients with PCOS.
* Patients diagnosed with autoimmune diseases (eg. Systemic Lupus erythematosus, multiple sclerosis, rheumatoid arthritis).
* Patients with recent diagnosis (6 months) of chronic infectious disease (HPV, HBV, HCV, HIV, TBC).
* Patients with current treatment of immunosuppressant (eg. corticosteroids, monoclonal antibodies...).

**Maximum Age:** 45 Years

**Minimum Age:** 18 Years

**Sampling Method:** NON_PROBABILITY_SAMPLE

**Sex:** ALL

**Standard Ages:**

- ADULT

**Study Population:** The study population will consist of healthy patients with no history of RIF and RM which have undergone or are undergoing ART with oocyte donation and SET at IVI RMA Madrid, Valencia y Barcelona. Study subject candidates will be informed about the study once the inclusion criteria have been met. Data on reproductive outcomes, embryo development and perinatal and obstetric complications will be collected.

### Contacts Locations Module

#### Central Contacts

**Contact 1:**

**Email:** Diana.Alecsandru@ivirma.com

**Name:** Diana Alecsandru, PhD

**Phone:** +34 91 180 29 00

**Role:** CONTACT

**Contact 2:**

**Email:** juan.garcia.velasco@ivirma.com

**Name:** Juan Antonio Garcia Velasco, PhD

**Phone:** +34 91 180 29 00

**Role:** CONTACT

#### Locations

**Location 1:**

**City:** Madrid

**Contacts:**

***Contact 1:***

- **Name:** Juan A Garcia-Velasco, MD

- **Phone:** 341802900

- **Role:** CONTACT

***Contact 2:***

- **Name:** Juan A Garcia-Velasco, MD

- **Role:** PRINCIPAL_INVESTIGATOR

**Country:** Spain

**Facility:** Instituto Valenciano de Infertilidad

**Status:** RECRUITING

**Zip:** 28035

#### Overall Officials

**Official 1:**

**Affiliation:** IVIRMA MADRID

**Name:** Juan Antonio Garcia Velasco, PhD

**Role:** PRINCIPAL_INVESTIGATOR

### IPD Sharing Statement Module

**IPD Sharing:** NO

## Derived Section

### Misc Info Module

- Version Holder: 2024-05-24
